Skip to main content
GeneralHomeInvestorsNewsUzedy

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

By November 12, 2020March 15th, 2024No Comments1 min read